Treatment of high- and intermediate-high-risk pulmonary embolism by the Pulmonary Embolism Response Team: Focus on catheter-directed therapies.

Pulmonary Embolism Response Team catheter-directed therapies high-risk pulmonary embolism intermediate-high-risk pulmonary embolism pulmonary embolism

Journal

Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712

Informations de publication

Date de publication:
31 Jul 2023
Historique:
received: 24 04 2023
accepted: 27 06 2023
medline: 31 7 2023
pubmed: 31 7 2023
entrez: 31 7 2023
Statut: aheadofprint

Résumé

Multidisciplinary Pulmonary Embolism Response Teams (PERTs) were established to individualize the treatment of high-risk (HR) and intermediate-high-risk (IHR) pulmonary embolism (PE) patients, which pose a challenge in clinical practice. We retrospectively collected the data of all HR and IHR acute PE patients consulted by PERT CELZAT between September 2017 and October 2022. The patient population was divided into four different treatment methods: anticoagulation alone (AC), systemic thrombolysis (ST), surgical embolectomy (SE), and catheter-directed therapies (CDTx). Baseline clinical characteristics, risk stratification, PE severity parameters, and treatment outcomes were compared between the four groups. Of the 110 patients with HR and IHR PE, 67 (61%) patients were treated with AC only, 11 (10%) with ST, 15 (14%) underwent SE, and 17 (15%) were treated with CTDx. The most common treatment option in the HR group was reperfusion therapy, used in 20/24 (83%) cases, including ST in 7 (29%) patients, SE in 5 (21%) patients, and CTDx in 8 (33%) patients. In contrast, IHR patients were treated with AC alone in 63/86 (73%) cases. The in-hospital mortality rate was 9/24 (37.5%) in the HR group and 4/86 (4.7%) in the IHR group. The number of advanced procedures aimed at reperfusion was substantially higher in the HR group than in the IHR PE group. Despite the common use of advanced reperfusion techniques in the HR group, patient mortality remained high. There is a need further to optimize the treatment of patients with HR PE to improve outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Multidisciplinary Pulmonary Embolism Response Teams (PERTs) were established to individualize the treatment of high-risk (HR) and intermediate-high-risk (IHR) pulmonary embolism (PE) patients, which pose a challenge in clinical practice.
METHODS METHODS
We retrospectively collected the data of all HR and IHR acute PE patients consulted by PERT CELZAT between September 2017 and October 2022. The patient population was divided into four different treatment methods: anticoagulation alone (AC), systemic thrombolysis (ST), surgical embolectomy (SE), and catheter-directed therapies (CDTx). Baseline clinical characteristics, risk stratification, PE severity parameters, and treatment outcomes were compared between the four groups.
RESULTS RESULTS
Of the 110 patients with HR and IHR PE, 67 (61%) patients were treated with AC only, 11 (10%) with ST, 15 (14%) underwent SE, and 17 (15%) were treated with CTDx. The most common treatment option in the HR group was reperfusion therapy, used in 20/24 (83%) cases, including ST in 7 (29%) patients, SE in 5 (21%) patients, and CTDx in 8 (33%) patients. In contrast, IHR patients were treated with AC alone in 63/86 (73%) cases. The in-hospital mortality rate was 9/24 (37.5%) in the HR group and 4/86 (4.7%) in the IHR group.
CONCLUSIONS CONCLUSIONS
The number of advanced procedures aimed at reperfusion was substantially higher in the HR group than in the IHR PE group. Despite the common use of advanced reperfusion techniques in the HR group, patient mortality remained high. There is a need further to optimize the treatment of patients with HR PE to improve outcomes.

Identifiants

pubmed: 37519055
pii: VM/OJS/J/95272
doi: 10.5603/CJ.a2023.0047
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Arkadiusz Pietrasik (A)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.

Paweł Kurzyna (P)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland. paw.kurzyna@gmail.com.

Piotr Szwed (P)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center of Postgraduate Medical Education, European Health Center, Otwock, Poland.

Karolina Jasińska-Gniadzik (K)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.

Aleksandra Gąsecka (A)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.

Szymona Darocha (S)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center of Postgraduate Medical Education, European Health Center, Otwock, Poland.

Dariusz Zieliński (D)

Department of Cardiac Surgery, Medicover Hospital, Warsaw, Poland.

Łukasz Szarpak (Ł)

Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, United States.
Institute of Outcomes Research, Maria Sklodowska-Curie Medical Academy, Warsaw, Poland.

Janusz Kochman (J)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.

Marcin Grabowski (M)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.

Grzegorz Opolski (G)

1st Chair and Department of Cardiology, Medical University of Warsaw, Poland.

Adam Torbicki (A)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center of Postgraduate Medical Education, European Health Center, Otwock, Poland.

Marcin Kurzyna (M)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Center of Postgraduate Medical Education, European Health Center, Otwock, Poland.

Classifications MeSH